Metabolomic biomarkers of Multiple Sclerosis: a systematic review
journal contributionposted on 28.01.2021, 05:48 by L Porter, A Shoushtarizadeh, GA Jelinek, CR Brown, CK Lim, Alysha De Livera, KR Jacobs, TJ Weiland
© Copyright © 2020 Porter, Shoushtarizadeh, Jelinek, Brown, Lim, de Livera, Jacobs and Weiland. Background: Magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, and the McDonald’s clinical criteria are currently utilized tools in diagnosing multiple sclerosis. However, a more conclusive, consistent, and efficient way of diagnosing multiple sclerosis (MS) is yet to be discovered. A potential biomarker, discovered using advances in high-throughput sequencing such as nuclear magnetic resonance (NMR) spectroscopy and other “Omics”-based techniques, may make diagnosis and prognosis more reliable resulting in a more personalized and targeted treatment regime and improved outcomes. The aim of this review was to systematically search the literature for potential biomarkers from any bodily fluid that could consistently and accurately diagnose MS and/or indicate disease progression. Methods: A systematic literature review of EMBASE, PubMed (MEDLINE), The Cochrane Library, and CINAHL databases produced over a thousand potential studies. Inclusion criteria stated studies with potential biomarker outcomes for people with MS were to be included in the review. Studies were limited to those with human participants who had a clinically defined diagnosis of MS and published in English, with no limit placed on date of publication or the type of bodily fluid sampled. Results: A total of 1,805 studies were recorded from the literature search. A total of 1,760 studies were removed based on their abstract, with a further 18 removed after considering the full text. A total of 30 studies were considered relevant and had their data retrieved and analyzed. Due to the heterogeneity of focus and results from the refined studies, a narrative synthesis was favored. Conclusion: Several promising candidate biomarkers suitable for clinical application in MS have been studied. It is recommended follow-up studies with larger sample sizes be completed on several potential biomarkers.
GJ, TW, AL, and CB were all working in the Neuroepidemiology Unit, funded by philanthropic donations from a variety of sources.
JournalFrontiers in Molecular Biosciences
Pagination19p. (p. 1-19)
PublisherFrontiers Research Foundation
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineBiochemistry & Molecular BiologymetabolomicsMSmultiple sclerosismultiple sclerois and neuroimmunologysystematic (literature) reviewbiomarkerneuroimmunological diseasemetabolomics (OMICS)MAGNETIC-RESONANCE-SPECTROSCOPYCEREBROSPINAL-FLUID BIOMARKERSFATTY-ACIDSDISEASEGLUTAMATESERUMKYNURENINESDIAGNOSISPATHWAYLIPIDS